Drug Trial Radar · NCT04248855
Assessment of KAN-101 in Celiac Disease (ACeD)
Last checked: Nov 19, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Jan 21, 2020
Primary completion
Oct 8, 2021
Study completion Oct 8, 2021
Sponsor
- Lead sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SAIndustry
- Sponsor type
- Industry
- First posted
- Jan 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
Conditions
- Celiac Disease
Interventions
KAN-101Drug
Intravenous (IV) infusion
PlaceboDrug
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 28 Days
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials
Anaheim, California
Diablo Clinical Research
Walnut Creek, California
Innovative Medical Research of South Florida
Aventura, Florida
GCP Research
St. Petersburg, Florida
Tandem Clinical Research
Marrero, Louisiana
Parexel International- EPCU Baltimore
Baltimore, Maryland
West Michigan Clinical Research Center
Wyoming, Michigan
Mayo Clinic
Rochester, Minnesota
Celiac Disease Center at Columbia University
New York, New York
North Carolina Clinical Research
Raleigh, North Carolina
Aventiv Research
Columbus, Ohio
WR-ClinSearch, LLC
Chattanooga, Tennessee
Advanced Clinical Research
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.